Navigation Links
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Date:8/19/2007

product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. Both products are being developed in partnership with Merck Serono, a division of Merck KgA of Darmstadt, Germany. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its product candidate Kuvan; expectations regarding the Kuvan expanded access program; expectations regarding filings with regulatory agencies; and the development of 6R-BH4 for other indications. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of ongoing clinical trials related to Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities concerning Kuvan; results and timing of current and planned clinical trials of 6R-BH4 for other indications; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual R
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  BC Technical, the ... acquired Polaris Medical Imaging, a leader in sales, service ... strategic acquisition allows BC Technical to continue to expand ... within MR and CT modalities. "We ... said Mark Alvarez , president and CEO of ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... Research and Markets has announced ... Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the aspects ... and business performance of domestic major enterprises, as well ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... May 20 The owner and operator of a Houston-area ... program, announced the Departments of Justice and Health and Human Services (HHS). ... William M. ... fraud before U.S. District Judge David Hittner in U.S. District ...
... May 20 Inverness Medical Innovations, Inc. (NYSE: ... charge of their health at home through the merger of rapid ... Citi Global Health Care Conference being held May 26 through ... New York City .  Jon Russell, Vice President, Finance, will attend. ...
Cached Medicine Technology:Houston-Area Durable Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutrition Supplies 2Houston-Area Durable Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutrition Supplies 3
(Date:9/2/2014)... 02, 2014 Request A Test , a ... a 10% discount on all drug testing in September ... need to use promo code DRUG10 when placing their order. ... blood and hair. Drug testing is typically done in panels ... of the most popular panels include the 5 Panel Urine ...
(Date:9/2/2014)... 02, 2014 Michigan’s health care landscape ... Act and the Healthy Michigan Plan. Throughout these changes, ... a trusted funding resource for under-served individuals. Federal and ... or underinsured women between the ages of 50 and ... percent of the federal poverty level. , ...
(Date:9/2/2014)... ZAMST, a leader in high-performance sports prevention/protective ... baseball star Nolan Arenado . Widely considered ... Arenado will be working with Zamst to continue their ... , Arenado was selected by Colorado in the second ... Arenado was awarded the Gold Glove, putting him among ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Recently, Os-Monitor.com, ... programs, has announced its new collection of employee internet ... is now providing big discounts, up to 10% off, ... company is now selling more than 20 different kinds ... of them are very useful for companies of all ...
(Date:9/2/2014)... San Diego, CA (PRWEB) September 02, 2014 ... kicking coach Anthony Cantele of Cantele Kicking on his role ... a National Camp Series (NCS) Associate according to retired ... a great career at Kansas State University and is one ... Husted. “I had a chance to meet with Anthony at ...
Breaking Medicine News(10 mins):Health News:Request A Test Offers 10% Off Drug Testing in September 2014 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 3Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Gold Glove Baseball Star Nolan Arenado Signs With Zamst 2Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3
... , THURSDAY, May 12 (HealthDay News) -- Music ... finding of a study by Northwestern University researchers who compared ... "Lifelong musical training appears to confer advantages in at ... memory and the ability to hear speech in noise," study ...
... inhalers may increase a smoker,s chance of quitting, according to ... . This study is the first to assess ... smoking. The research, which was carried out by ... people who were enrolled in a programme to help them ...
... , WEDNESDAY, May 11 (HealthDay News) -- Autism takes ... underemployment and lost income among mothers, University of Pennsylvania ... for a child with autism, however high, are only ... on families should be considered whenever policymakers fund autism ...
... a patient,s knowledge of family medical history to estimate his ... cancer history are not highly accurate, according to a study ... the National Cancer Institute. Primary care physicians ... screening or referrals to specialists, for instanceon the results. ...
... also known as Lou Gehrig,s disease, may be an exception ... In a retrospective study of over 400 ALS patients, ... mildly obese survived longer than patients who were normal weight, ... the journal Muscle & Nerve and has been published online. ...
... (HealthDay News) -- Among teen boys with an autism ... with a greater degree of bullying behavior than their ... observation specifically reflects upon boys aged 12 to 18, ... intimidation, rumor-mongering and group exclusion that characterize bullying behavior. ...
Cached Medicine News:Health News:Musicians Maintain Memory, Hearing as They Age 2Health News:Autism Takes an Economic Toll on Mom's Job, Income: Study 2Health News:Autism Takes an Economic Toll on Mom's Job, Income: Study 3Health News:Autism Takes an Economic Toll on Mom's Job, Income: Study 4Health News:Patient reports of relatives' cancer history often not accurate 2Health News:Mild obesity appears to improve survival in ALS patients 2Health News:Teen Boys With Autism at Risk of Being Bullied: Study 2
... design includes several innovative features ... coating option for stable fixation ... bone preserving posterior stabilizing design, ... maximize range of motion, simple ...
Consensus Knee implants are designed to provide both joint and implant stability and allow near normal kinematics. The components are anatomic with porous and nonporous options. Six femoral/tibial an...
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively....
... Duracon tibial inserts have radiused A/P ... 4-axis machining, maximizing conformity of the ... of the femoral component. The resulting ... Duracon system, and accommodates the knee's ...
Medicine Products: